Table 2.

Changes in left and right ventricular volumes and associated parameters

VariablesTimes/WkBaseline Median (Q1, Q3)F12 Median (Q1, Q3)Adjusted Mean Changes from Baselinea (95% CI)Treatment Effectsa (95% CI)P Value
Daily trial
 LVEDV (ml)3167.6 (114.8, 255.4)174.4 (112.4, 247.2)−0.26% (−4.72% to 4.40%)−10.96% (−16.08% to −5.52%)<0.001
6163.2 (102.8, 248.0)146.6 (102.6, 215.6)−11.19% (−14.83% to −7.4%)
 LVESV (ml)369.2 (38.6, 126.3)71.3 (43, 117.8)0.46% (−6.69% to 8.15%)−14.84% (−22.66% to −6.23%)0.001
669.6 (35.8, 123.7)57.1 (33.4, 105.8)−14.45% (−20.03% to −8.47%)
 LV stroke volume (ml)393.2 (62.1, 151.3)94.1 (66.6, 140.9)0.32 (−4.68 to 5.32)−10.90 (−17.14 to −4.66)0.001
695.5 (62.9, 142.0)86.9 (56.9, 118.7)−10.58 (−15.19 to −5.97)
 LV ejection fraction (%)358.3 (41.5, 69.2)58.6 (44.8, 68.3)0.14 (−1.95 to 2.23)1.42 (−1.22 to 4.05)0.29
659.0 (45.6, 68.1)61 (46.6, 71)1.56 (−0.37 to 3.49)
 LVM/LVEDV (g/ml)376.0 (59.7, 102.5)74.2 (58.7, 108.7)−2.04 (−6.11 to 2.02)3.42 (−1.91 to 8.75)0.21
680.4 (56.9, 110.2)78.4 (58.2, 116.5)1.38 (−2.33 to 5.10)
 RVEDV (ml)3159.8 (104.2, 240.9)140.4 (90.6, 225.8)−9.08 (−14.98 to −2.76)−11.63% (−19.02% to −3.57%)0.006
6146.6 (96.5, 254.1)125.8 (78.9, 196.1)−19.65 (−24.44 to −14.56)
 RVESV (ml)369.4 (46, 118.5)63.1 (35, 104.5)−12.25% (−20.00% to −3.74%)−11.33% (−21.42% to 0.05%)0.05
672.2 (35.9, 114.5)53.7 (27.9, 97.3)−22.19% (−28.51% to −15.31%)
 RV stroke volume (ml)387.2 (50.4, 129.2)76.4 (50.1, 127.4)−5.39 (−11.05 to 0.27)−10.49 (−17.48 to −3.49)0.003
685.0 (51.3, 125.6)70.8 (42.5, 101.3)−15.87 (−21.1 to −10.65)
 RV ejection fraction (%)353.1 (40, 65.5)54.0 (43.4, 68.4)1.30 (−1.04 to 3.63)0.00 (−2.95 to 2.96)>0.99
654.3 (43.3, 65.1)56.0 (42.0, 68.4)1.30 (−0.85 to 3.44)
Nocturnal trial
 LVEDV (ml)3141.7 (98.9, 214.6)138.3 (106.9, 228.5)3.94% (−5.03% to 13.76%)−5.30% (−16.42% to 7.29%)0.39
6166.8 (109.8, 249.4)160 (98.6, 255.6)−1.57% (−10.27% to 7.97%)
 LVESV (ml)359.2 (35.3, 109.5)60.4 (35.9, 115.6)2.60% (−9.66% to 16.52%)−7.34% (−22.39% to 10.64%)0.40
675.7 (39.1, 138.2)67.5 (31.7, 117)−4.93% (−16.56% to 8.32%)
 LV stroke volume (ml)383.3 (52, 119.1)84.5 (59.9, 121.9)4.08% (−3.68 to 11.84)−2.97 (−13.75 to 7.8)0.58
692.3 (55.8, 118.4)82.6 (63.9, 140.9)1.11% (−6.84 to 9.06)
 LV ejection fraction (%)358.5 (42.1, 69.2)58.7 (44.4, 70.5)0.78 (−2.21 to 3.76)0.28 (−3.85 to 4.42)0.89
654.1 (37.8, 70.8)58.1 (35.6, 71.9)1.06 (−2.00 to 4.12)
 LVM/LVEDV (g/ml)381.5 (62.9, 137.7)80.4 (58.3, 120.1)−3.48 (−10.55 to 3.59)−1.49 (−10.98 to 7.99)0.76
677.7 (58.4, 123)76.5 (54.5, 120.1)−4.97 (−12.2 to 2.26)
 RVEDV (ml)3131.3 (79.8, 200)116.8 (80.6, 199.7)−9.05% (−18.04% to 0.92%)0.83% (−12.66% to 16.41%)0.91
6147.6 (89.8, 202.6)132 (75, 231)−8.3% (−17.57% to 2.02%)
 RVESV (ml)362.9 (31.9,114.7)54.8 (32.2, 113.4)−9.85% (−20.74% to 2.53%)−3.84% (−19.59% to 15.00%)0.66
673.6 (44.1, 101)61.3 (27.9, 117.1)−13.31% (−24.03% to −1.08%)
 RV stroke volume (ml)367.6 (39.3, 103.8)67.5 (39.9, 107.5)−5.54 (−14.16 to 3.08)3.27 (−8.31 to 14.86)0.58
673.6 (47.5, 118)64.1 (46.9, 110)−2.27 (−11.09 to 6.56)
 RV ejection fraction (%)352.1 (34.1, 67.7)51.8 (38.1, 66.4)0.56 (−3.11 to 4.23)1.34 (−3.58 to 6.27)0.59
650.4 (40.9, 59.2)53.4 (41.9, 68.8)1.90 (−1.86 to 5.65)
  • Q, quartile; F12, month 12 of trial; 95% CI, 95% confidence interval; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LV, left ventricular; LVM, left ventricular mass; RVEDV, right ventricular end diastolic volume; RVESV, right ventricular end systolic volume; RV, right ventricular.

  • a Adjusted mean changes and treatment effects for LVEDV, LVESV, RDEDV, and RVESV expressed as percent difference based on log-transformed analysis.